amlodipine and Coronary Disease studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research Excerpts

Excerpt	Relevance	Reference
"The clinical efficacy of rosuvastatin, amlodipine, and aspirin markedly reduces the blood pressure indices, blood lipid indices, plasma viscosity, and platelet aggregation of patients with hypertension and coronary heart disease, improves LVEF, and has a good safety profile."	9.51	The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. ( Fu, J; Li, B; Wang, T; Zhao, N, 2022)
"Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery."	9.19	[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014)
"To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine."	9.17	[Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013)
"To evaluate the protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease."	9.16	[Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease]. ( Gao, M; Han, X; Hui, H; Li, K; Li, Z; Wang, J, 2012)
"To evaluate the efficacy and tolerability of the fixed combination: amlodipine + enalapril, when compared to amlodipine in the normalization of the diastolic arterial pressure (DAP) (<85 mmHg), in pts with CAD and systemic arterial hypertension (SAH)."	9.14	Combination of amlodipine and enalapril in hypertensive patients with coronary disease. ( Armagnajian, D; César, LA; Ferreira, JF; Gomes, EP; Mansur, Ade P; Moretti, MA; Nogueira, PR; Ramires, JA; Rienzo, M; Saraiva, JF, 2009)
"Fifty-nine hypertensive patients with associated coronary artery disease (stable angina pectoris) and isolated diastolic dysfunction were randomized to receive amlodipine (30 patients) or lacidipine (29 patients) for 4 weeks."	9.11	Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. ( Brazdzionyte, J; Jurkevicus, R; Zabiela, V; Zaliunas, R, 2005)
"Amlodipine 10 mg was evaluated for additional anti-ischaemic and anti-anginal efficacy in 14 patients pre-treated with a beta-blocker who had documented coronary artery disease, stable angina pectoris, and > or = 2 mm of exercise-induced ST segment depression."	9.07	Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. ( Beyerle, A; Lehmann, G; Reiniger, G; Rudolph, W, 1993)
"We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome."	7.74	Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008)
" We assessed the effects of the DHP calcium antagonist amlodipine on coronary hemodynamics and vascular response to sympathetic activation in patients with coronary heart disease."	7.69	Effects of amlodipine on coronary hemodynamics and vascular responses to sympathetic stimulation in patients with coronary heart disease. ( Alessio, P; Gregorini, L; Mancia, G; Perondi, R; Pomidossi, G; Rimini, A; Saino, A; Zanchetti, A, 1994)
"Only quinapril was associated with significant improvement in FMD, and this response is related to the presence of the insertion allele of the ACE genotype."	6.69	Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) ( Anderson, TJ; Charbonneau, F; Elstein, E; Haber, H, 2000)
"The clinical efficacy of rosuvastatin, amlodipine, and aspirin markedly reduces the blood pressure indices, blood lipid indices, plasma viscosity, and platelet aggregation of patients with hypertension and coronary heart disease, improves LVEF, and has a good safety profile."	5.51	The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. ( Fu, J; Li, B; Wang, T; Zhao, N, 2022)
" Experiments were undertaken to establish whether the chronic administration of amlodipine prevents the rise in blood pressure in spontaneously hypertensive rats (SHR), and whether it attenuates cardiac hypertrophy caused by hypertension."	5.27	The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988)
"Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery."	5.19	[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014)
"To compare the reduction in calculated Framingham 10 year coronary heart disease (CHD) risk after 52 weeks' intervention with a proactive multifactorial intervention (PMI) strategy (based on single-pill amlodipine/atorvastatin [SPAA]) versus continuing usual care (UC) (based on investigators' best clinical judgment) among younger (<65 years) and older (≥ 65 years) patients."	5.17	Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (< 65 years) and older (≥ 65 years) patients in the CRUCIAL trial. ( Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Yunis, C; Zamorano, J, 2013)
"A proactive, multifactorial intervention strategy incorporating single-pill amlodipine/atorvastatin (SPAA) (5-10/10 mg up-titrated to 5-10/20 mg, where approved) is more effective than physician's usual care (UC) for reducing calculated 10 year coronary heart disease (CHD) risk, in patients with hypertension and additional risk factors (CRUCIAL trial: Curr Med Res Opin 2011;27:821--33)."	5.17	Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. ( Hradec, J; Sutradhar, S; Zamorano, J, 2013)
"To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine."	5.17	[Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013)
"To evaluate the protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease."	5.16	[Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease]. ( Gao, M; Han, X; Hui, H; Li, K; Li, Z; Wang, J, 2012)
"We have reported the benefits of atorvastatin and of an amlodipine-based regimen on coronary heart disease (CHD) events in hypertensive patients in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)."	5.14	Coronary heart disease benefits from blood pressure and lipid-lowering. ( Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H, 2009)
"Stroke: common 'GG' homozygotes had higher risk on lisinopril versus amlodipine [hazard ratio (HR)=1."	5.14	Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009)
"To evaluate the efficacy and tolerability of the fixed combination: amlodipine + enalapril, when compared to amlodipine in the normalization of the diastolic arterial pressure (DAP) (<85 mmHg), in pts with CAD and systemic arterial hypertension (SAH)."	5.14	Combination of amlodipine and enalapril in hypertensive patients with coronary disease. ( Armagnajian, D; César, LA; Ferreira, JF; Gomes, EP; Mansur, Ade P; Moretti, MA; Nogueira, PR; Ramires, JA; Rienzo, M; Saraiva, JF, 2009)
"The aim of this study was to evaluate the effect of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in patients with hypertension uncomplicated by coronary heart disease in the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm)."	5.14	Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). ( Campbell, NR; Dahlöf, B; Dobson, JE; Poulter, NR; Sever, PS; Wedel, H, 2009)
"The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effects of a renin-angiotensin system blocker, benazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H)."	5.14	Cardiovascular events during differing hypertension therapies in patients with diabetes. ( Bakris, GL; Dahlöf, B; Devereux, RB; Hester, A; Hua, TA; Jamerson, K; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, EJ; Weber, MA; Weir, M, 2010)
"Stable patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks."	5.12	Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. ( Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006)
" Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4."	5.11	Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, M; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2005)
"Fifty-nine hypertensive patients with associated coronary artery disease (stable angina pectoris) and isolated diastolic dysfunction were randomized to receive amlodipine (30 patients) or lacidipine (29 patients) for 4 weeks."	5.11	Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. ( Brazdzionyte, J; Jurkevicus, R; Zabiela, V; Zaliunas, R, 2005)
"The Circadian Anti-ischemia Program in Europe (CAPE II) compared the efficacy of amlodipine and diltiazem (Adizem XL) and the combination of amlodipine/atenolol and diltiazem (Adizem XL)/isosorbide 5-mononitrate on exercise and ambulatory myocardial ischemia during regular therapy and after omission of medication."	5.10	Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. ( Beckerman, B; Brennan, C; Bultas, J; Deanfield, JE; Detry, JM; Lichtlen, PR; Sellier, P; Thaulow, E; Young, ST, 2002)
"The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)."	5.09	Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001)
" In the hypertensive patients with coronary disease the authors also evaluated sympathetic activation after double-blind, placebo-controlled administration of metoprolol (100 mg/day), followed by amlodipine (10 mg/day), quinapril (20 mg/day), and amlodipine (5 mg/day) plus quinapril (10 mg/day)."	5.08	Power spectral analysis of heart rate in elderly hypertensive subjects with or without silent coronary disease. ( Bucca, C; Cacciafesta, M; Di Gioacchino, C; Durante, M; Fimognari, FL; Lo Verde, A; Marigliano, V; Monteforte, G; Munizzi, MR; Piccirillo, G; Santagada, E; Tarantini, S; Viola, E, 1996)
"Amlodipine 10 mg was evaluated for additional anti-ischaemic and anti-anginal efficacy in 14 patients pre-treated with a beta-blocker who had documented coronary artery disease, stable angina pectoris, and > or = 2 mm of exercise-induced ST segment depression."	5.07	Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. ( Beyerle, A; Lehmann, G; Reiniger, G; Rudolph, W, 1993)
"The hemodynamic effects and antianginal efficacy of 10 mg amlodipine administered intravenously were assessed for 45 minutes in 18 subjects with stable angina pectoris."	5.06	Pharmacodynamics of amlodipine: hemodynamic effects and antianginal efficacy after atrial pacing. ( Grant, P; Gupta, S; Hillis, WS; Hogg, KJ; Hornung, RS; Singh, SP, 1989)
"The haemodynamic dose-response effects of a new long-acting slow-calcium channel blocking agent, amlodipine were evaluated in 20 patients with angiographically confirmed coronary heart disease."	5.06	A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease. ( Frais, MA; Jackson, NC; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1986)
"Aim To study the condition of coronary vasculature by data of coronarography (CG) in patients with chronic ischemic heart disease (IHD) and arterial hypertension (AH) associated with stage 2-4 chronic kidney disease (CKD) and to evaluate the effect of a 12-week complex treatment with perindopril or with a combination of perindopril/amlodipine on changes in vascular wall stiffness, endothelial function, and structure and function parameters in this patient category after coronary stenting."	4.02	[Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting]. ( Barbashina, TA; Gavriljuk, EV; Mal, GS; Pribylov, CA; Pribylov, VS; Pribylova, NN; Yakovleva, MV, 2021)
"We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome."	3.74	Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008)
" We assessed the effects of the DHP calcium antagonist amlodipine on coronary hemodynamics and vascular response to sympathetic activation in patients with coronary heart disease."	3.69	Effects of amlodipine on coronary hemodynamics and vascular responses to sympathetic stimulation in patients with coronary heart disease. ( Alessio, P; Gregorini, L; Mancia, G; Perondi, R; Pomidossi, G; Rimini, A; Saino, A; Zanchetti, A, 1994)
" With this end in mind, 21 patients with ischemic heart disease and arterial hypertension were divided into three groups of seven subjects each and submitted to different drug treatments with single daily doses: group 1 received isosorbide-5-mononitrate (60 mg), group 2 amlodipine (10 mg), and group 3 a combination of both drugs at the same dosage, for four weeks."	3.68	[The association of amlodipine with isosorbide-5-mononitrate in the treatment of ischemic-hypertensive cardiopathy]. ( D'Aprile, N; Faglia, S; Kristodhullo, A; Mondillo, S; Palazzuoli, V, 1992)
"Only quinapril was associated with significant improvement in FMD, and this response is related to the presence of the insertion allele of the ACE genotype."	2.69	Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) ( Anderson, TJ; Charbonneau, F; Elstein, E; Haber, H, 2000)
"Amlodipine has sustained vasodilatory effects and relieves coronary spasm, which may reduce luminal loss and clinical complications after PTCA."	2.69	Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). ( Buller, C; Endresen, K; Erikssen, J; Forfang, K; Goulet, G; Hansen, J; Jørgensen, B; Simonsen, S; Thaulow, E; Vatne, K; Webb, J, 2000)
"Treatment with diltiazem resulted in a significant lengthening of sinus cycle length (SCL, p < 0."	2.67	Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy. ( Biscione, F; Lanza, GA; Manzoli, A; Natale, A; Santarelli, P, 1994)
"The efficacy of amlodipine, a long half-life dihydropyridine calcium antagonist, at the dosage of 5-10 mg/day in a single daily administration, has been compared with that of nifedipine R, a short half-life dihydropyridine, at the dosage of 20-40 mg b."	2.67	Amlodipine versus nifedipine retard in the treatment of chronic ischemic heart disease. ( Cardillo, R; Castelli, D; Circo, A; Mangiameli, S; Platania, F; Scaccianoce, G, 1992)
" After a stable control period, dose-response curves were constructed for each drug with hemodynamics measured 10 minutes after intravenous boluses."	2.66	Comparative hemodynamic dose-response effects of five slow calcium channel-blocking agents in coronary artery disease. ( Frais, MA; Jackson, N; Midtbo, KA; Reynolds, G; Sharma, S; Silke, B; Taylor, SH; Verma, SP, 1987)
"Amlodipine therapy was also associated with significant slowing in carotid atherosclerosis, an important surrogate marker for CAD, independent of blood pressure changes."	2.41	Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. ( Mason, RP, 2002)
"Amlodipine also was associated with significant slowing of carotid atherosclerosis, an important surrogate marker for CAD, independent of blood pressure modification."	2.41	Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease. ( Mason, RP, 2001)
"Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally."	2.39	Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. ( Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995)
"Amlodipine is a dihydropyridine calcium antagonist that has unique pharmacokinetic properties."	2.38	The efficacy of amlodipine in the management of ischaemic heart disease. ( McGibney, D, 1991)
"Treatment with amlodipine was found to reduce myocardial oxygen demand, improve recovery of peak developed tension, have a favourable effect on Ca2+ fluxes, improve retention of tissue adenosine triphosphate and creatine phosphate, and reduce acidosis in the ischaemic/reperfused myocardium."	2.38	The pharmacological profile of amlodipine in relation to ischaemic heart disease. ( Burges, RA, 1991)
"Amlodipine is a dihydropyridine calcium antagonist with a unique pharmacokinetic profile providing advantages over other therapies of its kind."	2.38	A review of amlodipine in myocardial ischaemia. ( Taylor, SH, 1991)
"Amlodipine has also been found to be effective in reducing the anginal attack rate in patients with vasospastic angina."	2.38	The efficacy of amlodipine in myocardial ischemia. ( Taylor, SH, 1989)
"Heart failure was four times more frequent in these patients with renal disease than in other hypertensives."	1.33	[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. ( Aguilar-Llopis, A; Arístegui-Urrestarazu, R; Cosín-Aguilar, J; Hernándiz-Martínez, A; Masramón-Morell, X; Rodríguez-Padial, L; Zamorano-Gómez, JL, 2006)
" Therefore, the new once-daily calcium antagonist amlodipine is safe and efficacious in non-hypertensive patients with coronary artery disease."	1.29	Safety and efficacy of amlodipine. A new once-daily calcium antagonist in non-hypertensive patients with coronary artery disease. ( Ogawa, T; Sugishita, Y; Tomizawa, T; Yasui, K, 1993)
"4."	1.28	Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol. ( Dalipram, RA; Dusting, GJ; Sobey, CG; Woodman, OL, 1992)
"Amlodipine is a long-acting dihydropyridine calcium antagonist with vascular selectivity."	1.28	Vascular and myocardial effects of amlodipine: an overview. ( Gu, XH; Nayler, WG, 1991)
"Amlodipine is a long-acting dihydropyridine-based Ca2+ channel blocker, developed for use on a once-daily basis."	1.28	Amlodipine pretreatment and the ischemic heart. ( Nayler, WG, 1989)
" Experiments were undertaken to establish whether the chronic administration of amlodipine prevents the rise in blood pressure in spontaneously hypertensive rats (SHR), and whether it attenuates cardiac hypertrophy caused by hypertension."	1.27	The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988)

Research

Studies (111)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Change From Baseline in DBP at Month 12

Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4

Change From Baseline in SBP at Month 12

Change From Baseline in Systolic Blood Pressure (SBP) at Month 4

European SCORE 10-year Risk of Fatal CVD at Month 4

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (10.81)	18.7374
1990's	38 (34.23)	18.2507
2000's	44 (39.64)	29.6817
2010's	15 (13.51)	24.3611
2020's	2 (1.80)	2.80

Authors	Studies
Pribylova, NN	1
Yakovleva, MV	1
Pribylov, CA	1
Barbashina, TA	1
Gavriljuk, EV	1
Mal, GS	1
Pribylov, VS	1
Fu, J	1
Wang, T	1
Li, B	1
Zhao, N	1
Haywood, LJ	4
Davis, BR	12
Piller, LB	2
Simpson, LM	3
Ghosh, A	1
Einhorn, PT	2
Ford, CE	8
Probstfield, JL	2
Soliman, EZ	1
Wright, JT	6
Kim, JH	1
Zamorano, J	3
Erdine, S	1
Pavia, A	2
Al-Khadra, A	1
Sutradhar, S	3
Yunis, C	2
Hradec, J	1
Oparil, S	2
Cushman, WC	5
Furberg, CD	5
Habib, GB	1
Margolis, K	1
Whelton, PK	5
Kalyuzhin, VV	1
Teplyakov, AT	1
Pushnikova, EY	1
Bespalova, LD	1
Kalyuzhina, EV	1
Kolesnikov, RN	1
Tepliakov, AE	1
Pushnikova, EIu	1
Kaliuzhin, VV	1
Bespalova, ID	1
Kaliuzhina, EV	1
Kaliuzhina, MI	1
Galeeva, ZM	1
Galiavich, AS	1
Weintraub, WS	1
Spertus, JA	1
Kolm, P	1
Maron, DJ	1
Zhang, Z	1
Jurkovitz, C	1
Zhang, W	1
Hartigan, PM	1
Lewis, C	1
Veledar, E	1
Bowen, J	1
Dunbar, SB	1
Deaton, C	1
Kaufman, S	1
O'Rourke, RA	1
Goeree, R	1
Barnett, PG	1
Teo, KK	1
Boden, WE	1
Mancini, GB	3
Kostis, JB	2
Black, HR	3
Farber, MA	1
Levy, D	1
Massie, BM	1
Nawaz, S	1
Menzin, J	1
Boulanger, L	1
Tang, S	1
Thakker, K	1
Nissen, SE	1
Sever, PS	3
Poulter, NR	3
Mastorantonakis, S	1
Chang, CL	1
Dahlof, B	4
Wedel, H	3
Lynch, AI	2
Boerwinkle, E	3
Eckfeldt, JH	4
Leiendecker-Foster, C	3
Arnett, DK	3
Rienzo, M	1
Saraiva, JF	1
Nogueira, PR	1
Gomes, EP	1
Moretti, MA	1
Ferreira, JF	1
Armagnajian, D	1
Mansur, Ade P	1
Ramires, JA	1
César, LA	1
Scheen, AJ	1
Krzesinski, JM	1
Dobson, JE	1
Campbell, NR	1
Weber, MA	1
Bakris, GL	1
Jamerson, K	1
Weir, M	1
Kjeldsen, SE	2
Devereux, RB	1
Velazquez, EJ	1
Kelly, RY	1
Hua, TA	1
Hester, A	1
Pitt, B	4
Vecherskiĭ, IuIu	1
Andreev, SL	1
Murashev, BIu	1
Rahman, M	2
Cutler, JA	2
Barzilay, JI	2
Brown, CD	1
Colon, PJ	1
Fine, LJ	1
Grimm, RH	2
Gupta, AK	1
Baimbridge, C	2
Henriquez, MA	1
Ilamaythi, E	1
Preston, R	1
Proschan, M	1
Graumlich, JF	1
Pavlik, V	1
Alderman, MH	2
Gordon, D	1
Franklin, SS	1
Blumenthal, SS	1
Castaldo, RS	1
Preston, RA	1
Hui, H	1
Li, K	1
Li, Z	1
Wang, J	1
Gao, M	1
Han, X	1
Deanfield, JE	2
Detry, JM	1
Sellier, P	1
Lichtlen, PR	2
Thaulow, E	7
Bultas, J	1
Brennan, C	1
Young, ST	1
Beckerman, B	1
Mason, RP	2
Wepner, U	1
Dens, J	1
Desmet, W	1
Piessens, J	1
Jørgensen, B	4
Siragy, HM	1
Ohbayashi, Y	1
Tsutamoto, T	1
Sakaguchi, T	1
Tanaka, T	1
Kanamori, T	1
Yokohama, H	1
Sichiri, G	1
Hukai, D	1
Okabayashi, T	1
Ozawa, T	1
Ishii, C	1
Tsutsui, T	1
Ohno, K	1
Ohnishi, M	1
Wada, A	1
Yamazaki, T	1
Taniguchi, I	1
Kurusu, T	1
Shimazu, Y	1
Hashizume, Y	1
Takikawa, K	1
Kuwata, M	1
Onodera, T	1
Yoshikawa, M	1
Mochizuki, S	1
Kuwajima, I	1
Kapanadze, S	1
Dolidze, N	1
Bakhutashvili, Z	1
Chapidze, L	1
Shengelia, E	1
Pressel, S	2
Nwachuku, C	3
Barzilay, J	3
Batuman, V	1
Farber, M	1
Henriquez, M	1
Kopyt, N	1
Louis, GT	2
Saklayen, M	1
Stanford, C	1
Walworth, C	1
Ward, H	1
Wiegmann, T	1
Traut, V	1
Iwai, K	1
Morimoto, S	1
Matsumoto, M	1
Iiamathi, E	1
Leenen, FH	2
Margolis, KL	1
Mathis, DE	1
Moloo, J	1
Panebianco, D	1
Parish, DC	1
Simmons, DL	1
Thadani, U	3
Zaliunas, R	1
Jurkevicus, R	1
Zabiela, V	1
Brazdzionyte, J	1
Füessl, HS	1
Miller, MB	1
Black, H	1
Nwachuku, CE	1
Atlas, SA	1
Basile, JN	2
Cuyjet, AB	1
Dart, R	1
Felicetta, JV	1
Jafri, SZ	1
Proschan, MA	1
Stone, PH	1
Gratsiansky, NA	1
Blokhin, A	1
Huang, IZ	1
Meng, L	1
Messerli, FH	1
Staessen, JA	1
Cosín-Aguilar, J	1
Hernándiz-Martínez, A	1
Arístegui-Urrestarazu, R	1
Masramón-Morell, X	1
Aguilar-Llopis, A	1
Rodríguez-Padial, L	1
Zamorano-Gómez, JL	1
Rahn, KH	1
Davis, B	1
Marginean, H	1
Basile, J	1
Wong, ND	1
Whelton, P	1
Dart, RA	1
Navarro Estrada, JL	1
Oliveri, R	3
Steffen, HM	1
Perondi, R	2
Saino, A	2
Zanchetti, A	2
Mancia, G	2
Santarelli, P	1
Biscione, F	1
Natale, A	1
Manzoli, A	1
Lanza, GA	1
Pomidossi, G	1
Gregorini, L	1
Rimini, A	1
Alessio, P	1
Lehmann, G	1
Reiniger, G	1
Beyerle, A	1
Rudolph, W	1
Mehta, JL	1
Ogawa, T	1
Yasui, K	1
Tomizawa, T	1
Sugishita, Y	1
Piccirillo, G	1
Fimognari, FL	1
Santagada, E	1
Munizzi, MR	1
Viola, E	1
Monteforte, G	1
Bucca, C	1
Durante, M	1
Di Gioacchino, C	1
Tarantini, S	1
Lo Verde, A	1
Cacciafesta, M	1
Marigliano, V	1
Little, WC	1
Cheng, CP	1
Elvelin, L	1
Nordlander, M	1
Freysz, M	1
Timour, Q	1
Bernaud, C	1
Bertrix, L	1
Faucon, G	1
Mulcahy, D	1
Madjlessi-Simon, T	1
Fillette, F	1
Mary-Krause, M	1
Lechat, P	1
Jaillon, P	1
Poole-Wilson, PA	1
Jörgensen, B	2
Byington, RP	1
Miller, ME	2
Herrington, D	1
Riley, W	1
Hunninghake, DB	1
de Vries, RJ	1
Anthonio, R	1
van Veldhuisen, DJ	1
Scholtens, E	1
Buikema, H	1
van Gilst, WH	1
Handrock, R	1
Herzig, S	1
Endresen, K	3
Forfang, K	3
Simonsen, S	3
Fisher, LD	1
Klinge, R	1
Sirnes, PA	1
Hall, C	1
Fragasso, G	1
Xuereb, RG	1
Xuereb, M	1
Rossetti, E	1
Margonato, A	1
Chierchia, SL	1
Egeland, T	1
Høstmark, AT	1
Anderson, TJ	1
Elstein, E	1
Haber, H	1
Charbonneau, F	1
Miller, M	1
Byington, R	2
Hunninghake, D	1
Vatne, K	1
Hansen, J	1
Webb, J	1
Buller, C	1
Goulet, G	1
Erikssen, J	1
Bech, J	1
Madsen, JK	1
Kelbaek, H	1
Clarkson, P	1
Mullen, MJ	1
Donald, AE	1
Powe, AJ	1
Thomson, H	1
Thorne, SA	1
Bull, T	1
Schillaci, G	1
Verdecchia, P	1
Vita, JA	1
Yeung, AC	1
Winniford, M	1
Jones, CL	1
Goff, DC	1
Ciocon, JO	1
Sweeney, ME	1
Randall, OS	1
Pieper, JA	1
Beevers, G	1
Caulfield, M	1
Collins, R	1
McInnes, GT	1
Mehlsen, J	1
Nieminen, M	1
O'Brien, E	1
Ostergren, J	1
Collier, DJ	1
Bernardi, L	1
Angell-James, JE	1
Caulfield, MJ	1
Sleight, P	1
Williams, C	1
Evans, GW	1
Sobey, CG	1
Dalipram, RA	1
Dusting, GJ	1
Woodman, OL	1
Palazzuoli, V	1
Mondillo, S	1
Faglia, S	1
D'Aprile, N	1
Kristodhullo, A	1
Circo, A	1
Scaccianoce, G	1
Platania, F	1
Castelli, D	1
Cardillo, R	1
Mangiameli, S	1
Oganov, RG	1
Gratsianskiĭ, NA	1
Mazur, NA	1
Lazebnik, LB	1
Belousov, IuB	1
Sidorenko, BA	1
Ol'binskaia, LI	1
Vertkin, AL	1
Shevchenko, OP	1
Karpov, IuA	1
McGibney, D	1
Burges, RA	1
Nayler, WG	3
Gu, XH	1
Taylor, SH	7
Navarro Estrada, J	1
Saglietti, H	2
Dimarco, M	1
Casabé, H	2
Caponnetto, S	1
Canale, C	1
Terrachini, V	1
Masperone, MA	1
Bruzzone, F	1
Silke, B	5
Verma, SP	5
Zezulka, AV	1
Sharma, S	2
Reynolds, G	3
Jackson, NC	2
Guy, S	1
Hoff, PT	1
Tamura, Y	1
Lucchesi, BR	1
Goldhammer, E	1
Sharma, SK	3
Jackson, N	2
Hogg, KJ	1
Hornung, RS	1
Hillis, WS	1
Gupta, S	1
Grant, P	1
Singh, SP	1
Estrada, JN	1
Di Marco, M	1
Rämö, MP	1
Plowden, JS	1
Gabel, M	1
Millard, RW	2
Lathrop, DA	1
Dunlap, ED	1
Matlib, MA	1
Gross, GJ	1
Farber, NE	1
Pieper, GM	1
Frais, MA	2
Midtbo, KA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice[NCT00407537]	Phase 4	1,531 participants (Actual)	Interventional	2007-03-31	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation[NCT00007657]	Phase 3	3,260 participants (Anticipated)	Interventional	1998-12-31	Completed
Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.[NCT00825604]	Phase 2	0 participants (Actual)	Interventional	2009-01-31	Withdrawn (stopped due to Because of poor inclusion difficulties to find patient)
Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status[NCT04475094]		75 participants (Anticipated)	Observational	2019-12-23	Recruiting
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950]	Phase 3	11,506 participants (Actual)	Interventional	2003-10-31	Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.)
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981]	Phase 4	154 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901]		37,939 participants (Actual)	Observational	2000-09-30	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day[NCT00091429]	Phase 3	500 participants	Interventional	2004-08-31	Completed
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention[NCT03044964]	Phase 4	40 participants (Anticipated)	Interventional	2017-01-10	Recruiting
A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)[NCT02651415]	Phase 2	12 participants (Actual)	Interventional	2016-08-31	Completed
Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart[NCT00211081]		12 participants (Actual)	Interventional	2004-11-30	Completed
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes[NCT03085771]	Phase 2	30 participants (Anticipated)	Interventional	2017-01-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mmHg (Least Squares Mean)
Caduet	-10.0128
Usual Care	-6.8429

Intervention	mmHG (Least Squares Mean)
Caduet	-8.3024
Usual Care	-6.6908

Intervention	mmHg (Least Squares Mean)
Caduet	-18.2409
Usual Care	-12.4903

Intervention	mmHG (Least Squares Mean)
Caduet	-15.3088
Usual Care	-12.1619

European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4

European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12

Intervention	percent risk (Mean)
Caduet	3.1
Usual Care	3.7

European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12

Framingham 10-year Risk of Stroke at Month 12

Intervention	percent risk (Mean)
Caduet	3.0
Usual Care	3.7

"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 12

Framingham 10-year Risk of Stroke at Month 4

Intervention	percent risk (Mean)
Caduet	3.7
Usual Care	4.9

Framingham 10-year Risk of Total CHD at Month 4

Intervention	percent risk (Mean)
Caduet	3.7
Usual Care	4.9

Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4

Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12

Intervention	percent risk (Mean)
Caduet	12.5
Usual Care	16.3

Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12

Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD

Intervention	percent risk (Mean)
Caduet	12.5
Usual Care	16.3

European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12

Change From Baseline in Framingham 10-year Risk of Developing Total CHD

Intervention	percent risk (Least Squares Mean)
	Month 4	Month 12
Caduet	-1.8438	-1.9693
Usual Care	-0.9678	-0.9963

Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12

Change From Baseline in Lipid Parameters at Month 12

Intervention	percent risk (Least Squares Mean)
	Month 4	Month 12
Caduet	-7.2705	-7.2374
Usual Care	-2.5155	-2.5167

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Baseline, Month 12

Change From Baseline in Lipid Parameters at Month 4

Intervention	mg/dL (Least Squares Mean)
	TC	LDL	HDL	Triglycerides
Caduet	-37.1024	-33.2420	-0.4339	-15.2270
Usual Care	-4.0368	-3.4168	-1.0105	3.0398

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4

Mean Lipid Parameters at Month 12

Intervention	mg/dL (Least Squares Mean)
	TC	LDL	HDL	Triglycerides
Caduet	-42.7542	-38.2765	-0.2060	-20.5645
Usual Care	-3.8144	-2.9628	-1.1978	3.0828

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 12

Mean Lipid Parameters at Month 4

Intervention	mg/dL (Mean)
	TC	LDL	HDL	Triglycerides
Caduet	163.3	87.1	47.3	151.5
Usual Care	196.6	117.3	47.1	166.4

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 4

Mean Systolic and Diastolic Blood Pressure at Month 12

Mean Systolic and Diastolic Blood Pressure at Month 4

Number of Participants With Increase of Treatment Dosages After 4 Months.

Intervention	mg/dL (Mean)
	TC	LDL	HDL	Triglycerides
Caduet	156.0	80.9	47.6	143.5
Usual Care	195.2	116.4	46.8	164.8

Intervention	mmHg (Mean)
	Systolic	Diastolic
Caduet	130.6	79.2
Usual Care	134.3	81.1

Intervention	mmHg (Mean)
	Systolic	Diastolic
Caduet	133.5	80.7
Usual Care	134.5	81.1

Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4

Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months

Intervention	Participants (Number)
	Increased dose	increased dose of anti-hypertensive medications	increased dose of lipid lowering medications	increase in either medication	increase in both medications
Caduet	30	30	0	4	0
Usual Care	90	88	2	45	0

Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4, Month 12

Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months

Intervention	participants (Number)
	Month 4: anti-hypertensive and/or lipid lowering	Month 4: anti-hypertensive	Month 4: lipid lowering	Month 4: anti-hypertensive and lipid lowering	Month 12: anti-hypertensive and/or lipid lowering	Month 12: anti-hypertensive	Month 12: lipid lowering	Month 12: anti-hypertensive and lipid lowering
Caduet	648	647	45	44	655	654	46	45
Usual Care	642	637	202	197	642	638	208	204

Goals set at <140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and <140/90 mm Hg or <130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines. (NCT00407537)
Timeframe: Month 4, Month 12

Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months

Intervention	percentage of participants (Number)
	JNC Month 4	JNC Month 12	ESC Month 4	ESC Month 12
Caduet	65.2	76.1	48.6	58.2
Usual Care	62.6	60.6	46.0	47.5

Goal set at <100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at <80 mg/dL according to the European (EU) Society of Cardiology guidelines. (NCT00407537)
Timeframe: Month 4, Month 12

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Intervention	Percentage of participants (Number)
	US Month 4	US Month 12	EU Month 4	EU Month 12
Caduet	77.3	71.9	52.4	46.7
Usual Care	28.2	28.8	13.3	11.5

CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Intervention	Percentage of Patients with an Event (Number)
Benazepril/Amlodipine	5.0
Benazepril/Hydrochlorothiazide	6.3

Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

Intervention	Percentage of Patients with an Event (Number)
Benazepril/Amlodipine	8.6
Benazepril/Hydrochlorothiazide	10.3

CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Median Time Course to Development of Worst Grade (Grade 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

Intervention	Percentage of Patients with an event (Number)
Benazepril/Amlodipine	9.6
Benazepril/Hydrochlorothiazide	11.8

Median time course for participants to develop worst grade 3 HFSR toxicity is defined as the time (days) from start date of study drug to date of first documented grade 3 HFSR toxicity and will be calculated only for patients who had a HFSR toxicity grade 3. (NCT02651415)
Timeframe: p to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

Median Time to Progression Free Survival (PFS)

Intervention	days (Median)
Single Arm Trial	12

Median time (in months) to PFS. PFS is defined as the time from start date of study drugs to the date of first documented disease progression (radiological or clinical) or death due to any cause, if death occurs before progression is documented. PFS will be evaluated based on RECIST v1.1 criteria, 20% progression or any new lesion. (NCT02651415)
Timeframe: From start date of study drugs to the date of first documented disease progression or death due to any cause.

Number of Participants That Have Any Grade HFSR Toxicity

Intervention	Months (Median)
Single Arm Trial	2.60

"The trial will measure the toxicities of HFSR in participants receiving both perindopril and regorafenib using the CTCAE v4.03 criteria.~The toxicity of HFSR will be expressed based on the number of participants in the study (N=10) who are experiencing HFSR of all grades." (NCT02651415)
Timeframe: Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

Number of Participants With Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

Intervention	Participants (Count of Participants)
Single Arm Trial	7

The number of participants that experienced an HFSR of grade 3 or above as assessed by CTCAE v4.03 criteria when treated with a combination of regorafenib and perindopril. (NCT02651415)
Timeframe: Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

The Number of Participants That Experienced All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

Intervention	Participants (Count of Participants)
Single Arm Trial	5

All grades of adverse events (including HFSR) will be evaluated using CTCAE v4.03, at baseline and at D1 of each cycle while they are on the study drug and during the 30-day follow-up period (Post therapy). (NCT02651415)
Timeframe: At baseline and at D1 of each cycle while on the study drug and during the 30-day follow-up period

The Number of Participants That Experienced Any Grade of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

Intervention	participants (Number)
Single Arm Trial	10

All grades of hypertension will be evaluated using CTCAE v4.03, weekly for the first six weeks while they are on the study drug, then every second week and during the 30-day follow-up period (Post therapy). (NCT02651415)
Timeframe: Weekly for the first six weeks while on the study drug, then every second week and during the 30-day follow-up period

Change in Flow Mediated Dilation

Intervention	Participants (Count of Participants)
Single Arm Trial	6

Flow-mediated dilation of the brachial artery will be measured using high-resolution ultrasound. Arterial diameter will be measured above the small cavity in the elbow joint from ultrasound images at rest in response to an increase in blood flow to the area. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)

C-Reactive Protein Level

Intervention	Percentage of brachial artery diameter (Mean)
Spironolactone	5.5

The normal reference range for C-reactive protein is as follows: CRP: 0-10mg/L (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)

Interleukin 1 Beta (IL1b) Level

Intervention	mg/L (Median)
	Baseline	4 Week Follow Up
Spironolactone	1.10	1.10

The normal result for IL1b is <3.9 pg/mL. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)

Interleukin-10 (IL10) Level

Intervention	pg/mL (Median)
	Baseline	4 Week Follow Up
Spironolactone	.38	.23

The normal result for IL-10 for Interleukin 10 is < 18pg/ml. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)

Interleukin-6 (IL-6) Level

Intervention	18pg/ml (Median)
	Baseline	4 Week Follow Up
Spironolactone	.26	.13

The normal result for IL-6 for Interleukin 6 is < 5pg/ml. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)

Tumor Necrosis Factor-Alpha (TNF-a) Level

Intervention	pg/ml (Median)
	Baseline	4 Week Follow Up
Spironolactone	1.96	1.54

The normal result for TNF-a is <5.6 pg/mL. (NCT00211081)
Timeframe: Baseline, Post-Intervention (4 Weeks)

Article	Year
Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis, 2002, Volume: 165, Issue:2 Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Diabetes Complications; Diabetes Mellitus; E	2002
An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. American heart journal, 2003, Volume: 145, Issue:3 Topics: Amlodipine; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Confidence Intervals; Coronary	2003
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3 Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert	2004
[Treatment of hypertension in elderly patients with coronary heart disease]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-	2005
Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:3 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Coronary Disease; Hu	2006
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:5 Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Hum	1995
Clinical promise of calcium antagonists in the angioplasty patient. European heart journal, 1997, Volume: 18 Suppl B Topics: Amlodipine; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Combined Modality Therapy; Cor	1997
Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease. Pharmacotherapy, 2001, Volume: 21, Issue:9 Pt 2 Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Coronary Disease; Endothelium, Vascul	2001
Management of coronary heart disease risk factors and progression with calcium channel blockers. Pharmacotherapy, 2001, Volume: 21, Issue:9 Pt 2 Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Ar	2001
The efficacy of amlodipine in the management of ischaemic heart disease. Postgraduate medical journal, 1991, Volume: 67 Suppl 3 Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Drug Therapy, Combination;	1991
The pharmacological profile of amlodipine in relation to ischaemic heart disease. Postgraduate medical journal, 1991, Volume: 67 Suppl 3 Topics: Amlodipine; Animals; Calcium Channel Blockers; Cats; Coronary Disease; Dogs; Mice; Muscle Contractio	1991
A review of amlodipine in myocardial ischaemia. Postgraduate medical journal, 1991, Volume: 67 Suppl 5 Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; H	1991
Cardioprotective effects of amlodipine on ischemia and reperfusion in two experimental models. The American journal of cardiology, 1990, Nov-20, Volume: 66, Issue:18 Topics: Amlodipine; Animals; Calcium Channel Blockers; Cats; Coronary Disease; Dogs; In Vitro Techniques; My	1990
The efficacy of amlodipine in myocardial ischemia. American heart journal, 1989, Volume: 118, Issue:5 Pt 2 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel	1989

Article	Year
The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. Disease markers, 2022, Volume: 2022 Topics: Amlodipine; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypertension; Lipids; Platel	2022
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. Journal of the National Medical Association, 2018, Volume: 110, Issue:4 Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C	2018
Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (< 65 years) and older (≥ 65 years) patients in the CRUCIAL trial. Current medical research and opinion, 2013, Volume: 29, Issue:5 Topics: Age Factors; Aged; Amlodipine; Coronary Disease; Drug Combinations; Female; Heptanoic Acids; Humans;	2013
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Current medical research and opinion, 2013, Volume: 29, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinatio	2013
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension (Dallas, Tex. : 1979), 2013, Volume: 61, Issue:5 Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido	2013
[Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. Terapevticheskii arkhiv, 2013, Volume: 85, Issue:5 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angina, Stable; Atenolol; Calcium Channel	2013
[The influence of amlodipine on transcapillary metabolism of oxygen during coronary heart disease with insulin resistance]. Klinicheskaia meditsina, 2013, Volume: 91, Issue:4 Topics: Amlodipine; Capillary Permeability; Coronary Circulation; Coronary Disease; Humans; Insulin Resistan	2013
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. Terapevticheskii arkhiv, 2014, Volume: 86, Issue:9 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, D	2014
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine, 2008, Aug-14, Volume: 359, Issue:7 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C	2008
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation, 2008, Nov-25, Volume: 118, Issue:22 Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl	2008
Coronary heart disease benefits from blood pressure and lipid-lowering. International journal of cardiology, 2009, Jun-26, Volume: 135, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressur	2009
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:6 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel	2009
Combination of amlodipine and enalapril in hypertensive patients with coronary disease. Arquivos brasileiros de cardiologia, 2009, Volume: 92, Issue:3 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Ed	2009
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). Journal of the American College of Cardiology, 2009, Sep-22, Volume: 54, Issue:13 Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Europe;	2009
Cardiovascular events during differing hypertension therapies in patients with diabetes. Journal of the American College of Cardiology, 2010, Jun-29, Volume: 56, Issue:1 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B	2010
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Pharmacogenetics and genomics, 2012, Volume: 22, Issue:5 Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll	2012
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clinical journal of the American Society of Nephrology : CJASN, 2012, Volume: 7, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub	2012
Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial. Current medical research and opinion, 2012, Volume: 28, Issue:10 Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Cholesterol; Coronary Disease; Drug Combinations;	2012
[Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:11 Topics: Aged; Amlodipine; Contrast Media; Coronary Angiography; Coronary Disease; Female; Humans; Kidney Dis	2012
Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. Journal of the American College of Cardiology, 2002, Sep-04, Volume: 40, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Calcium Channel B	2002
Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. American heart journal, 2003, Volume: 145, Issue:6 Topics: Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Angi	2003
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Current hypertension reports, 2003, Volume: 5, Issue:4 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone	2003
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. Journal of cardiovascular pharmacology, 2003, Volume: 42 Suppl 1 Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Co	2003
Effect of amlodipine on vascular responses after coronary stenting compared with an angiotensin-converting enzyme inhibitor. Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:4 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Coronary Angiography; Coronary Disease;	2004
Pleiotropic effects of cardilopin (secondary coronary prevention). Georgian medical news, 2005, Issue:119 Topics: Amlodipine; Blood Pressure; Blood Pressure Monitors; Calcium Channel Blockers; Coronary Disease; End	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Jun-27, Volume: 165, Issue:12 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Chlorthalidone; Coronary Disease; Diabetes	2005
Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. Acta cardiologica, 2005, Volume: 60, Issue:3 Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Angiography; Coronary Disease;	2005
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. The pharmacogenomics journal, 2007, Volume: 7, Issue:2 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Chlorthalido	2007
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:3 Topics: Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Glucose; Blood	2006
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. Journal of the American College of Cardiology, 2006, Aug-01, Volume: 48, Issue:3 Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met	2006
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. Journal of the American College of Cardiology, 2006, Aug-01, Volume: 48, Issue:3 Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met	2006
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. Journal of the American College of Cardiology, 2006, Aug-01, Volume: 48, Issue:3 Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met	2006
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. Journal of the American College of Cardiology, 2006, Aug-01, Volume: 48, Issue:3 Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met	2006
Long-term efficacy of amlodipine in patients with severe coronary artery disease. Journal of cardiovascular pharmacology, 1993, Volume: 22 Suppl A Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Coronary Disease; Exercise Test; Female; Follow-U	1993
[Amlodipine in heart failure: initial results of the PRAISE study]. Herz, 1995, Volume: 20 Suppl 2 Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Coronary Disease; Double-Blind Method	1995
Coronary vascular reactivity and calcium antagonist therapy in patients with angina. Journal of cardiovascular pharmacology, 1994, Volume: 24 Suppl A Topics: Amlodipine; Angina Pectoris; Blood Pressure; Coronary Circulation; Coronary Disease; Drug Evaluation	1994
Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy. Cardiovascular drugs and therapy, 1994, Volume: 8, Issue:4 Topics: Adult; Aged; Amlodipine; Atenolol; Coronary Disease; Diltiazem; Drug Therapy, Combination; Electroph	1994
Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. European heart journal, 1993, Volume: 14, Issue:11 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Coronary Disease; Double-Blind Method; Exe	1993
Power spectral analysis of heart rate in elderly hypertensive subjects with or without silent coronary disease. Angiology, 1996, Volume: 47, Issue:1 Topics: Aged; Algorithms; Amlodipine; Antihypertensive Agents; Case-Control Studies; Coronary Disease; Doubl	1996
Pointers from recent multicentre trials using ambulatory monitoring--placing placebo in perspective. European heart journal, 1995, Volume: 16, Issue:12 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Coronary Disease; Drug Therapy,	1995
Effects of amlodipine on transient myocardial ischaemia in patients with a severe coronary condition treated with a beta-blocker. Amlor-Holter Study Investigators. European heart journal, 1995, Volume: 16, Issue:12 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Coronary Circulation; Coronary Disease; Double	1995
Attenuated physical exercise capacity in smokers compared with non-smokers after coronary angioplasty despite similar luminal diameters. European heart journal, 1998, Volume: 19, Issue:5 Topics: Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiogr	1998
Analysis of arrhythmias in the Circadian Antiischemia Program in Europe (CAPE) study. Journal of cardiovascular pharmacology, 1999, Volume: 33, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Arrhythmias, Cardiac; Calci	1999
N-terminal proatrial natriuretic peptide in angina pectoris: impact of revascularization by angioplasty. International journal of cardiology, 1999, Volume: 68, Issue:1 Topics: Adult; Age Factors; Aged; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Atrial Natriu	1999
Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids. European heart journal, 1999, Volume: 20, Issue:19 Topics: Amlodipine; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Female; Humans;	1999
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1 Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal	2000
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1 Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal	2000
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1 Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal	2000
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1 Topics: Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cal	2000
Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigator Archives of internal medicine, 2000, Feb-14, Volume: 160, Issue:3 Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Amlodipine; Canada; Cholesterol, LDL; Coro	2000
Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). Journal of the American College of Cardiology, 2000, Mar-01, Volume: 35, Issue:3 Topics: Amlodipine; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Angiography; Coronary	2000
Amlodipine reduces myocardial ischaemia during exercise without compromising left ventricular function in patients with silent ischaemia: a randomised, double-blind, placebo-controlled study. European journal of heart failure, 1999, Volume: 1, Issue:4 Topics: Aged; Amlodipine; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Cross-Over Studi	1999
The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. Atherosclerosis, 2001, Volume: 154, Issue:1 Topics: Adult; Amlodipine; Brachial Artery; Calcium Channel Blockers; Coronary Disease; Double-Blind Method;	2001
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes care, 2001, Volume: 24, Issue:4 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant	2001
Amlodipine versus nifedipine retard in the treatment of chronic ischemic heart disease. La Clinica terapeutica, 1992, Volume: 140, Issue:1 Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Chronic Disease; Coronary Disease; Delayed-Action	1992
Anti-ischaemic properties of amlodipine, a new calcium antagonist, in patients with severe coronary artery disease: a prospective trial. Postgraduate medical journal, 1991, Volume: 67 Suppl 5 Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Exercise Test; Female; Hear	1991
Open comparative study to assess the efficacy and safety of two calcium antagonists, amlodipine and diltiazem, in the treatment of symptomatic myocardial ischaemia. Postgraduate medical journal, 1991, Volume: 67 Suppl 5 Topics: Amlodipine; Angina Pectoris; Coronary Disease; Diltiazem; Hemodynamics; Humans; Middle Aged; Nifedip	1991
An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease. Cardiovascular drugs and therapy, 1990, Volume: 4, Issue:2 Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiac Output; Coronary Disease; Diltiazem;	1990
Pharmacodynamics of amlodipine: hemodynamic effects and antianginal efficacy after atrial pacing. American heart journal, 1989, Volume: 118, Issue:5 Pt 2 Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiac Catheterization; Cardiac Pacing, Arti	1989
Antiischemic properties of amlodipine, a new calcium antagonist, in patients with severe coronary artery disease: a prospective trial. American heart journal, 1989, Volume: 118, Issue:5 Pt 2 Topics: Aged; Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Exercise Tes	1989
A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease. Herz, 1986, Volume: 11, Issue:6 Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output;	1986
Comparative hemodynamic dose-response effects of five slow calcium channel-blocking agents in coronary artery disease. Clinical pharmacology and therapeutics, 1987, Volume: 42, Issue:4 Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Diltiazem; Dose-Re	1987

Article	Year
[Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting]. Kardiologiia, 2021, Aug-31, Volume: 61, Issue:8 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Combinations; Humans; Hy	2021
Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure: findings from the CAMELOT economic substudy. Applied health economics and health policy, 2008, Volume: 6, Issue:2-3 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2008
[Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease]. Revue medicale de Liege, 2009, Volume: 64, Issue:4 Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Coronary Disease; Drug Combinations; Huma	2009
What your blood pressure isn't revealing. The Johns Hopkins medical letter health after 50, 2010, Volume: 22, Issue:9 Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp	2010
[New aspects of using dihydropyridine calcium antagonists during coronary bypass surgery]. Terapevticheskii arkhiv, 2010, Volume: 82, Issue:12 Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Disease; Dose-Response Relati	2010
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Statistics in medicine, 2013, Feb-28, Volume: 32, Issue:5 Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth	2013
[Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!]. MMW Fortschritte der Medizin, 2003, Jan-16, Volume: 145, Issue:1-2 Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert	2003
[Patients with coronary disease and normal blood pressure: amlodipine vs. enalapril -- regarding the contribution in DMW 4/2005]. Deutsche medizinische Wochenschrift (1946), 2005, May-20, Volume: 130, Issue:20 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci	2005
[Antihypertensive therapy: campaign of the giants]. MMW Fortschritte der Medizin, 2005, Dec-15, Volume: 147, Issue:51-52 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; D	2005
[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. Revista espanola de cardiologia, 2006, Volume: 59, Issue:10 Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Di	2006
[Treating essential hypertension. Are beta blockers still first choice?]. MMW Fortschritte der Medizin, 2007, May-03, Volume: 149, Issue:18 Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor	2007
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Diabetes care, 2008, Volume: 31, Issue:2 Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S	2008
Effects of amlodipine on coronary hemodynamics and vascular responses to sympathetic stimulation in patients with coronary heart disease. Journal of cardiovascular pharmacology, 1994, Volume: 24, Issue:6 Topics: Adult; Aged; Amlodipine; Coronary Disease; Hemodynamics; Humans; Injections, Intravenous; Male; Midd	1994
Emerging options in the management of myocardial ischemia. The American journal of cardiology, 1994, Jan-27, Volume: 73, Issue:3 Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Disease	1994
Safety and efficacy of amlodipine. A new once-daily calcium antagonist in non-hypertensive patients with coronary artery disease. Japanese heart journal, 1993, Volume: 34, Issue:5 Topics: Amlodipine; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Coronary Disease; Drug Admini	1993
Cardiac implications of amlodipine-dantrolene combinations. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1996, Volume: 43, Issue:1 Topics: Amlodipine; Animals; Calcium Channel Blockers; Coronary Disease; Dantrolene; Drug Interactions; Drug	1996
Amlodipine in chronic heart failure. The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14 Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Chronic Disease; Coronary Angiography	1997
Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). The American journal of cardiology, 1997, Oct-15, Volume: 80, Issue:8 Topics: Aged; Amlodipine; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Double-Blind Meth	1997
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction. Journal of cardiovascular pharmacology, 1997, Volume: 30, Issue:5 Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Disease Models, Ani	1997
[Amlodipine]. Deutsche medizinische Wochenschrift (1946), 1998, Jan-02, Volume: 123, Issue:1-2 Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; He	1998
Long-term preservation of left ventricular function in medically treated patients with coronary artery disease and persistent exercise-induced ischemia. Cardiologia (Rome, Italy), 1999, Volume: 44, Issue:3 Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Atenolol; Cardiovascular Agents; Coronary Disease; Data In	1999
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2000, Volume: 1, Issue:9 Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2000
Coronary artery reactivity after treatment with simvastatin. Current atherosclerosis reports, 2001, Volume: 3, Issue:2 Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary V	2001
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. Journal of human hypertension, 2001, Volume: 15 Suppl 1 Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Human	2001
Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease. Journal of human hypertension, 2001, Volume: 15 Suppl 1 Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2001
Amlodipine PREVENTS angina, not atherosclerosis. Pharmacotherapy, 2002, Volume: 22, Issue:3 Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Artery Disease; Coronary Disease; Di	2002
Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). The American journal of cardiology, 2002, Jun-15, Volume: 89, Issue:12 Topics: Amlodipine; Calcium Channel Blockers; Coronary Angiography; Coronary Artery Disease; Coronary Diseas	2002
Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol. British journal of pharmacology, 1992, Volume: 105, Issue:3 Topics: Acetylcholine; Allopurinol; Amlodipine; Animals; Calcium Channel Blockers; Coronary Disease; Coronar	1992
[The association of amlodipine with isosorbide-5-mononitrate in the treatment of ischemic-hypertensive cardiopathy]. La Clinica terapeutica, 1992, Volume: 141, Issue:7 Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; Drug Evaluat	1992
[Circadian rhythm in the clinical course of cardiovascular diseases. Clinical experience using Norvasc (amlodipine) in the treatment of patients with ischemic heart disease and arterial hypertension]. Kardiologiia, 1992, Volume: 32, Issue:5 Topics: Amlodipine; Circadian Rhythm; Coronary Disease; Humans; Hypertension	1992
[24-hour protection and control: a new era of calcium antagonists. Amlodipine provides 24 hours of efficacy and safety]. Medicina clinica, 1992, Feb-29, Volume: 98, Issue:8 Topics: Amlodipine; Calcium Channel Blockers; Circadian Rhythm; Coronary Disease; Humans; Hypertension; Nife	1992
Vascular and myocardial effects of amlodipine: an overview. Postgraduate medical journal, 1991, Volume: 67 Suppl 5 Topics: Amlodipine; Animals; Arteriosclerosis; Binding Sites; Calcium Channel Blockers; Cardiomegaly; Cerebr	1991
Haemodynamic and radionuclide effects of amlodipine in coronary artery disease. British journal of clinical pharmacology, 1990, Volume: 29, Issue:4 Topics: Adult; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Corona	1990
The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. Journal of cardiovascular pharmacology, 1988, Volume: 12 Suppl 7 Topics: Aging; Amlodipine; Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Coronar	1988
Circadian variation in myocardial ischemia: the 24-hour antianginal effect of amlodipine. Proceedings of a symposium. Monte Carlo, Monaco, April 7, 1989. American heart journal, 1989, Volume: 118, Issue:5 Pt 2 Topics: Amlodipine; Calcium Channel Blockers; Circadian Rhythm; Coronary Disease; Humans; Nifedipine	1989
A hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease. American heart journal, 1989, Volume: 118, Issue:5 Pt 2 Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Diltiazem; Female; Hemodynamics; Humans; Mal	1989
Amlodipine pretreatment and the ischemic heart. The American journal of cardiology, 1989, Nov-07, Volume: 64, Issue:17 Topics: Acidosis; Adenosine Triphosphate; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Coronary D	1989
Amlodipine, a long-acting calcium antagonist drug reduces ischemia-induced ventricular conduction delay in pig hearts. The American journal of cardiology, 1989, Nov-07, Volume: 64, Issue:17 Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Electrophysiology;	1989
Protection of regional mechanics and mitochondrial oxidative phosphorylation by amlodipine in transiently ischemic myocardium. The American journal of cardiology, 1989, Nov-07, Volume: 64, Issue:17 Topics: Amlodipine; Animals; Biomechanical Phenomena; Calcium Channel Blockers; Coronary Circulation; Corona	1989
Effect of amlodipine on myocardial functional and metabolic recovery following coronary occlusion and reperfusion in dogs. Cardiovascular drugs and therapy, 1989, Volume: 3, Issue:4 Topics: Adenine Nucleotides; Amlodipine; Animals; Calcium Channel Blockers; Coronary Disease; Coronary Vesse	1989

amlodipine and Coronary Disease